Zobrazeno 241 - 250
of 2 582
pro vyhledávání: ''
Autor:
Alexandra Sevko, Ludmila Umansky, Jochen Utikal, Christoffer Gebhardt, Antje Sucker, Huanhuan Jiang, Kathrin Tarnanidis, Philipp Beckhove, Viktor Umansky, Dirk Schadendorf, Tim Holland-Letz, Ramtin Lichtenberger, Maike Reith
Publikováno v:
Clinical Cancer Research. 21:5453-5459
Purpose: Immunotherapy with ipilimumab improves the survival of patients with metastatic melanoma. Because only around 20% of patients experience long-term benefit, reliable markers are needed to predict a clinical response. Therefore, we sought to d
Autor:
Walter J. Urba, Richard Fuerstenberg, Frances R. Bahjat, Yoshinobu Koguchi, Alan J. Korman, Christina Maria Milburn, Shelly Bambina, Brendan D. Curti, Helena M. Hoen, Keith S. Bahjat, Michael Rynning
Publikováno v:
Cancer Research. 75:5084-5092
Treatment with ipilimumab improves overall survival (OS) in patients with metastatic melanoma. Because ipilimumab targets T lymphocytes and not the tumor itself, efficacy may be uniquely sensitive to immunomodulatory factors present at the time of tr
Autor:
Henrik J. Ditzel, Daniel Elias, Maria Bibi Lyng, Martin Bak, Carla Maria Lourenco Alves, Anne E. Lykkesfeldt
Publikováno v:
Cancer Research. 75:A2-17
Estrogen receptor positive (ER+) breast cancer accounts for over 80% of breast cancers and these patients are eligible for endocrine therapy. Despite the efficacy of endocrine treatment many patients experience recurrence or disease progression as a
Autor:
Gary Spitzer, Nikhil C. Munshi, Adam D. Cohen, Michael A. Caligiuri, Robert Zerbib, Yvonne A. Efebera, Sundar Jagannath, Craig C. Hofmeister, Don M. Benson, Pascale Andre
Publikováno v:
Clinical Cancer Research. 21:4055-4061
Purpose: Natural killer (NK) cells may play an important role in the immune response to multiple myeloma; however, multiple myeloma cells express killer immunoglobulin-like receptor (KIR) ligands to prevent NK cell cytotoxicity. Lenalidomide can expa
Autor:
Luigi Formisano, Erika Martinelli, Matilde Lambiase, Francesca Fenizia, Roberto Bianco, Floriana Morgillo, Fortunato Ciardiello, Giulia Martini, Donata Vitagliano, Teresa Troiani, Claudia Cardone, Nicola Normanno, Davide Ciardiello, Stefania Napolitano
Publikováno v:
Clinical Cancer Research. 21:4153-4164
Purpose: The use of cetuximab in the treatment of metastatic colorectal cancer is limited by development of resistance. Experimental Design: We have investigated in three models of highly epidermal growth factor receptor (EGFR)–dependent colorectal
Autor:
V. Craig Jordan
Publikováno v:
Cancer Research. 77:4545-4547
[][1] On June 7, 2017, the cancer research community lost Professor Angela MH Brodie, PhD, FAACR, the “Mother of Aromatase Inhibitors.” The discovery of specific aromatase inhibitors (AI) is a major advance in targeted therapeutics. Three cheap o
Autor:
Laurent Boissel, Shahrooz Rabizadeh, Kayvan Niazi, Frances Toneguzzo, Patrick Soon-Shiong, L Zhou, Hans G. Klingemann
Publikováno v:
Cancer Research. 77:P2-04
Background. The ability of NK cells to kill cancer cells makes them an attractive choice for clinical immunotherapy. Early phase clinical trials in patients (pts) with advanced cancers have demonstrated the safety of activated NK (aNK [NK-92]) cells,
Autor:
D'ambrosio Mariantonietta, Martina Troiani, Simone Mosole, Ajinkya Revandkar, Ilaria Guccini, Andrea Alimonti, Emiliano Pasquini, Colucci Manuel
Publikováno v:
Cancer Research. 80:LB-005
Recent studies have raised fundamental questions about the possibility that senescence induced either by oncogene activation or chemotherapy, while initially restricting tumorigenesis, may promote cancer metastases at a late stage. This coexisting di
Autor:
Constance J. Temm, Kenneth A. Kesler, Nabil Adra, Muhammad T. Idrees, Neda Hashemi Sadraei, David A. Boothman, Lawrence H. Einhorn
Publikováno v:
Cancer Research. 80:5169-5169
Background: Testicular germ cell tumor (GCT) is the most common cancer in young men between 15 and 35 years of age. Cisplatin-based combination chemotherapy will cure 70% of patients with metastatic GCT. Patients who relapse can still be cured with s
Publikováno v:
Cancer Research. 80:1864-1864
Epidermal Growth Factor Receptor (EGFR) overexpression is observed in a large subset of patients with non-small-cell lung cancer (NSCLC) and correlated with poor prognosis. Current approved treatment for EGFR mutation-positive NSCLC has been revoluti